GLP-1 Drugs: Beyond Weight Loss, Serious Risks Emerge

GLP-1 medications such as Ozempic and Wegovy, initially for type 2 diabetes, are now popular for weight loss, offering benefits against heart disease and cognitive decline.

However, these powerful drugs can lead to gastrointestinal issues like nausea and constipation, affecting up to 44% of users. Slowed digestion is a key factor in these common symptoms.

More severe risks include pancreatitis, gallstones, and dehydration, which can lead to kidney failure. Intestinal obstruction, where food movement halts, is another serious concern.

Dental health is also a notable risk. Reduced saliva production from GLP-1s increases the incidence of dry mouth, gum disease, and cavities.

Doctors emphasize that symptoms like vomiting require immediate medical attention, as they can signal more dangerous side effects. Gastroparesis, a permanent condition affecting stomach function, is a rare but serious risk.

Patients must stay hydrated, prioritize protein intake, and avoid eating close to bedtime to mitigate risks. Long-term effects and potential unknown risks are still being studied.

It is crucial for patients to communicate any new or worsening symptoms to their healthcare providers. A thorough risk-benefit assessment, especially for those not medically indicated, is advised.